

SEQUENCE LISTING

<110> Banerjee, Subhashis
 Taylor, Lori K
 Spiegler, Clive E
 Tracey, Daniel E
 Chartash, Elliot K
 Hoffman, Rebecca S
 Barchuk, William T
 Yan, Philip
 Murtaza, Anwar
 Salfeld, Jochen G
 Fischkoff, Steven

<120> TREATMENT OF VASCULITIDES USING TNF α INHIBITORS

<130> BPI-196

<140>

<141>

<150> 60/397,275

<151> 2002-07-19

<150> 60/411,081

<151> 2002-09-16

<150> 60/417,490

<151> 2002-10-10

<150> 60/455,777

<151> 2003-03-18

<160> 37

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 1

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
1				5				10						15	
Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Arg	Asn	Tyr
		20						25					30		
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
		35					40					45			
Tyr	Ala	Ala	Ser	Thr	Leu	Gln	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
	50				55					60					
Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
65				70					75					80	
Glu	Asp	Val	Ala	Thr	Tyr	Tyr	Cys	Gln	Arg	Tyr	Asn	Arg	Ala	Pro	Tyr
				85					90					95	

BPI-196

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 2
 <211> 121
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Mutated human antibody

<400> 2
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
 20 25 30
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val
 50 55 60
 Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly
 100 105 110
 Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 3
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Thr or Ala
 <223> Mutated human antibody

<400> 3
 Gln Arg Tyr Asn Arg Ala Pro Tyr Xaa
 1 5

<210> 4
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> VARIANT
 <222> 12
 <223> Xaa = Tyr or Asn
 <223> Mutated human antibody

<400> 4

BPI-196

Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Xaa
1 5 10

<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 5
Ala Ala Ser Thr Leu Gln Ser
1 5

<210> 6
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 6
Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val Glu
1 5 10 15
Gly

<210> 7
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 7
Arg Ala Ser Gln Gly Ile Arg Asn Tyr Leu Ala
1 5 10

<210> 8
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 8
Asp Tyr Ala Met His
1 5

<210> 9
<211> 107
<212> PRT

BPI-196

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 9

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Tyr
          20          25          30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
          35          40          45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
          50          55          60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70          75          80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Tyr
          85          90          95
Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
          100          105

```

<210> 10

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 10

```

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
 1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
          20          25          30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val
          35          40          45
Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val
          50          55          60
Glu Gly Arg Phe Ala Val Ser Arg Asp Asn Ala Lys Asn Ala Leu Tyr
65          70          75          80
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
          85          90          95
Thr Lys Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Asn Trp Gly
          100          105          110
Gln Gly Thr Leu Val Thr Val Ser Ser
          115          120

```

<210> 11

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 11

```

Gln Lys Tyr Asn Ser Ala Pro Tyr Ala
 1           5

```

BPI-196

<210> 12
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 12
Gln Lys Tyr Asn Arg Ala Pro Tyr Ala
1 5

<210> 13
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 13
Gln Lys Tyr Gln Arg Ala Pro Tyr Thr
1 5

<210> 14
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 14
Gln Lys Tyr Ser Ser Ala Pro Tyr Thr
1 5

<210> 15
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 15
Gln Lys Tyr Asn Ser Ala Pro Tyr Thr
1 5

<210> 16
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

BPI-196

<400> 16

Gln Lys Tyr Asn Arg Ala Pro Tyr Thr
1 5

<210> 17

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 17

Gln Lys Tyr Asn Ser Ala Pro Tyr Tyr
1 5

<210> 18

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 18

Gln Lys Tyr Asn Ser Ala Pro Tyr Asn
1 5

<210> 19

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 19

Gln Lys Tyr Thr Ser Ala Pro Tyr Thr
1 5

<210> 20

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 20

Gln Lys Tyr Asn Arg Ala Pro Tyr Asn
1 5

<210> 21

<211> 9

<212> PRT

BPI-196

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 21

Gln Lys Tyr Asn Ser Ala Ala Tyr Ser
1 5

<210> 22

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 22

Gln Gln Tyr Asn Ser Ala Pro Asp Thr
1 5

<210> 23

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 23

Gln Lys Tyr Asn Ser Asp Pro Tyr Thr
1 5

<210> 24

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 24

Gln Lys Tyr Ile Ser Ala Pro Tyr Thr
1 5

<210> 25

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 25

Gln Lys Tyr Asn Arg Pro Pro Tyr Thr
1 5

BPI-196

<210> 26

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 26

Gln Arg Tyr Asn Arg Ala Pro Tyr Ala

1

5

<210> 27

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 27

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Asn

1

5

10

<210> 28

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 28

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Lys

1

5

10

<210> 29

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 29

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Tyr

1

5

10

<210> 30

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

BPI-196

<400> 30

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Asp
1 5 10

<210> 31

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 31

Ala Ser Tyr Leu Ser Thr Ser Phe Ser Leu Asp Tyr
1 5 10

<210> 32

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 32

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu His Tyr
1 5 10

<210> 33

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 33

Ala Ser Phe Leu Ser Thr Ser Ser Ser Leu Glu Tyr
1 5 10

<210> 34

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 34

Ala Ser Tyr Leu Ser Thr Ala Ser Ser Leu Glu Tyr
1 5 10

<210> 35

<211> 12

<212> PRT

BPI-196

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 35

Val	Ser	Tyr	Leu	Ser	Thr	Ala	Ser	Ser	Leu	Asp	Asn
1				5					10		

<210> 36

<211> 321

<212> DNA

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 36

gacatccaga	tgacccagtc	tccatcctcc	ctgtctgcat	ctgtagggga	cagagtcacc	60
atcacttgtc	gggcaagtca	gggcatcaga	aattacttag	cctgggtatca	gcaaaaacca	120
gggaaagccc	ctaagctcct	gatctatgct	gcatccactt	tgcaatcagg	gggtcccatct	180
cgggttcagt	gcagtggatc	tgggacagat	ttcactctca	ccatcagcag	cctacagcct	240
gaagatggtg	caacttatta	ctgtcaaagg	tataaccgtg	caccgtatac	ttttggccag	300
gggaccaagg	tggaatcaa	a				321

<210> 37

<211> 363

<212> DNA

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 37

gaggtgcagc	tggtggagtc	tgggggaggc	ttggtacagc	ccggcaggtc	cctgagactc	60
tcctgtgcgg	cctctggatt	cacctttgat	gattatgcc	tgcaactggg	ccggcaagct	120
ccagggaagg	gcctggaatg	ggtctcagct	atcacttgga	atagtgggtca	catagactat	180
gcggactctg	tggagggccg	attcaccatc	tccagagaca	acgccaagaa	ctccctgtat	240
ctgcaaata	acagtctgag	agctgaggat	acggccgtat	attactgtgc	gaaagtctcg	300
taccttagca	ccgcgtcctc	ccttgactat	tggggccaag	gtaccctggt	caccgtctcg	360
agt						363